robustic acid: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 54677407 |
| CHEMBL ID | 400777 |
| CHEBI ID | 92953 |
| SCHEMBL ID | 572212 |
| SCHEMBL ID | 15941305 |
| MeSH ID | M0274545 |
| Synonym |
|---|
| 5307-59-5 |
| BRD-K54411430-001-02-5 |
| DIVK1C_006709 |
| SPECTRUM_000556 |
| SPECTRUM4_001592 |
| SPECTRUM5_000304 |
| BSPBIO_003383 |
| NCGC00095552-01 |
| KBIOSS_001036 |
| KBIO2_003604 |
| KBIO3_002886 |
| KBIO2_006172 |
| KBIOGR_002204 |
| KBIO1_001653 |
| KBIO2_001036 |
| SPECTRUM3_001802 |
| SPECTRUM2_001165 |
| SPECPLUS_000613 |
| SPBIO_001149 |
| SPECTRUM240673 |
| robustic acid |
| CHEMBL400777 |
| LMPK12160025 |
| NCGC00095552-02 |
| 2h,8h-benzo(1,2-b:5,4-b')dipyran-2-one, 4-hydroxy-5-methoxy-3-(4-methoxyphenyl)-8,8-dimethyl- |
| CCG-39045 |
| SCHEMBL572212 |
| SCHEMBL15941305 |
| MBZKDBQDALOSRP-UHFFFAOYSA-N |
| 2h,8h-benzo[1,2-b:5,4-b']dipyran-2-one, 4-hydroxy-5-methoxy-3-(p-methoxyphenyl)-8,8-dimethyl- |
| 2h,8h-benzo[1,2-b:5,4-b']dipyran-2-one, 4-hydroxy-5-methoxy-3-(4-methoxyphenyl)-8,8-dimethyl- |
| 4-hydroxy-5-methoxy-3-(4-methoxyphenyl)-8,8-dimethyl-2h,8h-pyrano[3,2-g]chromen-2-one # |
| DTXSID30201149 |
| CHEBI:92953 |
| SR-05000002632-1 |
| sr-05000002632 |
| 6-hydroxy-5-methoxy-7-(4-methoxyphenyl)-2,2-dimethyl-8-pyrano[3,2-g][1]benzopyranone |
| Q27164688 |
| AKOS040753805 |
Robustic acid is reported to be a bioactive compound, isolated from the medicinal plant Dalbergia benthamii Prain.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Robustic acid is reported to be a bioactive compound, isolated from the medicinal plant Dalbergia benthamii Prain. " | ( Molecular Design, Synthesis and Docking Study of Alkyl and Benzyl Derivatives of Robustic Acid as Topoisomerase I Inhibitors. Chen, R; Huang, J; Huang, M; Huo, L; Jaiswal, Y; Liang, Y; Wei, J; Williams, L; Xia, X; Zhong, J, 2020) | 2.23 |
| Class | Description |
|---|---|
| organic hydroxy compound | An organic compound having at least one hydroxy group attached to a carbon atom. |
| isoflavonoid | Any 1-benzopyran with an aryl substituent at position 3. The term was originally restricted to natural products, but is now also used to describe semi-synthetic and fully synthetic compounds. |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 19.9526 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 19.9526 | 0.0251 | 20.2376 | 39.8107 | AID893 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 25.1189 | 0.1778 | 14.3909 | 39.8107 | AID2147 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 10.0000 | 0.1800 | 13.5574 | 39.8107 | AID1460 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 22.3872 | 0.0112 | 12.4002 | 100.0000 | AID1030 |
| glucocerebrosidase | Homo sapiens (human) | Potency | 1.9953 | 0.0126 | 8.1569 | 44.6684 | AID2101 |
| cellular tumor antigen p53 isoform a | Homo sapiens (human) | Potency | 7.1264 | 0.3162 | 12.4435 | 31.6228 | AID902; AID924 |
| thyroid hormone receptor beta isoform a | Homo sapiens (human) | Potency | 0.0001 | 0.0100 | 39.5371 | 1,122.0200 | AID1479 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 10.0000 | 0.6561 | 9.4520 | 25.1189 | AID927 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 6.3096 | 0.0316 | 10.2792 | 39.8107 | AID884; AID885 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Integrin beta-3 | Homo sapiens (human) | Potency | 7.9433 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Integrin alpha-IIb | Homo sapiens (human) | Potency | 7.9433 | 0.3162 | 11.4157 | 31.6228 | AID924 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 10.0000 | 1.5849 | 13.0043 | 25.1189 | AID927 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 6.3096 | 1.0000 | 12.2248 | 31.6228 | AID885 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1159550 | Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening | 2015 | Nature cell biology, Nov, Volume: 17, Issue:11 | 6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling. |
| AID311881 | Inhibition of Hsp90 | 2007 | Journal of natural products, Dec, Volume: 70, Issue:12 | Derrubone, an inhibitor of the Hsp90 protein folding machinery. |
| AID977599 | Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID977602 | Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM | 2013 | Molecular pharmacology, Jun, Volume: 83, Issue:6 | Structure-based identification of OATP1B1/3 inhibitors. |
| AID1159607 | Screen for inhibitors of RMI FANCM (MM2) intereaction | 2016 | Journal of biomolecular screening, Jul, Volume: 21, Issue:6 | A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (8.33) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 6 (50.00) | 24.3611 |
| 2020's | 2 (16.67) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.51) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (8.33%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 11 (91.67%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||